Skip to main content
Opus Genetics, Inc. logo

Opus Genetics, Inc. — Investor Relations & Filings

Ticker · IRD ISIN · US67577R1023 LEI · 529900C85NBMQFSETD92 US Manufacturing
Filings indexed 978 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country US United States of America
Listing US IRD

About Opus Genetics, Inc.

https://opusgtx.com/

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company that develops gene therapies to treat inherited retinal diseases (IRDs) and other retinal disorders. The company focuses on advancing treatments that address genetic mutations causing vision loss. Its pipeline targets conditions such as Leber congenital amaurosis (LCA), bestrophinopathy (Best disease), and retinitis pigmentosa (RP). The company's primary mission is to restore vision and prevent blindness by creating an efficient path to bring new therapies to the clinic for patients with inherited blinding conditions.

Recent filings

Filing Released Lang Actions
8-K - Opus Genetics, Inc. (0001228627) (Filer)
Regulatory Filings
2026-04-24 English
8-K - Opus Genetics, Inc. (0001228627) (Filer)
Regulatory Filings
2026-04-22 English
8-K - Opus Genetics, Inc. (0001228627) (Filer)
Regulatory Filings
2026-04-07 English
4 - Opus Genetics, Inc. (0001228627) (Issuer)
Director's Dealing
2026-03-18 English
4 - Opus Genetics, Inc. (0001228627) (Issuer)
Director's Dealing
2026-03-18 English
8-K - OPUS GENETICS, INC. (0001228627) (Filer)
Regulatory Filings
2026-02-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.